Why the study?
No effective treatment or prevention for recurrent Takotsubo syndrome has been identified, and understanding its pathophysiology is needed to enable personalized treatment.
A full understanding of the complex pathophysiology of Takotsubo syndrome, including genetic and neuro-cardiac factors, is required to develop effective personalized treatments.
Distinguishes primary vs secondary TTS triggers; leaves open personalized strategies pending prospective validation.
Takotsubo syndrome (TTS) consists of transient dysfunction of the left and/or right ventricle in the absence of ruptured plaque; thrombus or vessel dissection. TTS may be divided into two categories. Primary TTS occurs when the cause of hospitalization is the symptoms resulting from damage to the myocardium usually preceded by emotional stress. Secondary TTS occurs in patients hospitalized for other medical; surgical; anesthetic; obstetric or psychiatric conditions who have activation of their sympathetic nervous system and catecholamines release- they develop TTS as a complication of their primary condition or its treatment. There are several hypotheses concerning the cause of the disease. They include a decrease in estrogen levels; microcirculation dysfunction; endothelial dysfunction and the hypothesis based on the importance of the brain-heart axis. More and more research concerns the importance of genetic factors in the development of the disease. To date; no effective treatment or prevention of recurrent TTS has been found. Only when the pathophysiology of the disease is fully known; then personalized treatment will be possible.
No takes yet. Share an insight, caveat, or question.
Budnik et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: